Learning from nemolizumab: A promising therapy for prurigo nodularis - PubMed (original) (raw)

Editorial

. 2024 Jun;153(6):1548-1549.

doi: 10.1016/j.jaci.2024.02.016. Epub 2024 Mar 7.

Affiliations

Editorial

Learning from nemolizumab: A promising therapy for prurigo nodularis

Brian S Kim. J Allergy Clin Immunol. 2024 Jun.

No abstract available

Keywords: Atopic dermatitis; IL-31; IL-4Rα; dupilumab; nemolizumab; oncostatin M; prurigo nodularis.

PubMed Disclaimer

Conflict of interest statement

Disclosure statement Disclosure of potential conflict of interest: B. S. Kim is a cofounder of Alys Pharmaceuticals, and he has served as a consultant for 23andMe, ABRAX Japan, AbbVie, Almirall, Amgen, Arcutis Biotherapeutics, Arena Pharmaceuticals, argenx, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Clexio Biosciences, Eli Lilly and Company, Escient Pharmaceuticals, Evommune, Galderma, Genentech, GlaxoSmithKline, Granular Therapeutics, Incyte Corporation, Innovaderm Research, Janssen, Kiniksa, LEO Pharma, Maruho, Novartis, Pfizer, Recens Medical, Regeneron Pharmaceuticals, Sanofi, Septerna, Teva Pharmaceuticals, Triveni Bio, Vial, and WebMD; in addition, he has stock in ABRAX Japan, KliRNA Biotech, Locus Biosciences, and Recens Medical, he holds a patent for the use of JAK1 inhibitors for chronic pruritus, and he has a patent pending for the use of JAK inhibitors for interstitial cystitis.

Publication types

MeSH terms

Substances

LinkOut - more resources